Tumour progression or pseudoprogression? A review of post-treatment radiological appearances of glioblastoma

Clinical Radiology

Volumn 70, Issue 11, 2015, Pages 1299-1312

  Abdulla, S ^a   Saada, J ^a   Johnson, G ^b   Jefferies, S ^c   Ajithkumar, T ^c  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; GLIOBLASTOMA; HUMAN; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION WEIGHTED IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSEUDOPROGRESSION; RADIODIAGNOSIS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUSCEPTIBILITY WEIGHTED IMAGING; TUMOR DIFFERENTIATION; TUMOR GROWTH; ADULT; AGED; BRAIN NEOPLASMS; DISEASE COURSE; FEMALE; MALE; PATHOLOGY; PROCEDURES;

ADULT; AGED; BRAIN NEOPLASMS; DISEASE PROGRESSION; FEMALE; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MOLECULAR IMAGING;

EID: 84942985582     PISSN: 00099260     EISSN: 1365229X     Source Type: Journal    
DOI: 10.1016/j.crad.2015.06.096     Document Type: Review

References (103)

1. V.K.Y. Ho, J.C. Reijneveld, R.H. Enting, and et al. Changing incidence and improved survival of gliomas Eur J Cancer Oxf Engl 1990 2014 10.1016/j.ejca.2014.05.019 published online June 24
2. R. Stupp, W.P. Mason, M.J. van den Bent, and et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996
3. D.R. Macdonald, T.L. Cascino, S.C. Schold, and et al. Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol Off J Am Soc Clin Oncol 8 1990 1277 1280
4. A.J. Kumar, N.E. Leeds, G.N. Fuller, and et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment Radiology 217 2000 377 384
5. S. Ulmer, T.A. Braga, F.G. Barker, and et al. Clinical and radiographic features of peritumoral infarction following resection of glioblastoma Neurology 67 2006 1668 1670
6. M.C. Chamberlain, M.J. Glantz, L. Chalmers, and et al. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma J Neurooncol 82 2007 81 83
7. A.A. Brandes, A. Tosoni, F. Spagnolli, and et al. Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology Neuro-oncol 10 2008 361 367
8. C. Chaskis, B. Neyns, A. Michotte, and et al. Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations Surg Neurol 72 2009 423 428
9. J.L. Clarke, F.M. Iwamoto, J. Sul, and et al. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma J Clin Oncol Off J Am Soc Clin Oncol 27 2009 3861 3867
10. A. Fabi, M. Russillo, G. Metro, and et al. Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice Anticancer Res 29 2009 2607 2610
11. W. Taal, D. Brandsma, H.G. de Bruin, and et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide Cancer 113 2008 405 410
12. P.Y. Wen, D.R. Macdonald, D.A. Reardon, and et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group J Clin Oncol 28 2010 1963 1972
13. N. Verma, M.C. Cowperthwaite, M.G. Burnett, and et al. Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies Neuro-oncol 15 2013 515 534
14. P. Sanghera, R. Rampling, B. Haylock, and et al. The concepts, diagnosis and management of early imaging changes after therapy for glioblastomas Clin Oncol 24 2012 216 227
15. P.V. Tassel, J.M. Bruner, M.H. Maor, and et al. MR of toxic effects of accelerated fractionation radiation therapy and carboplatin chemotherapy for malignant gliomas AJNR Am J Neuroradiol 16 1995 715 726
16. M.E. Mullins, G.D. Barest, P.W. Schaefer, and et al. Radiation necrosis versus glioma recurrence: conventional mr imaging clues to diagnosis AJNR Am J Neuroradiol 26 2005 1967 1972
17. C.A. Valéry, B. Marro, O. Boyer, and et al. Extent of tumor-brain interface: a new tool to predict evolution of malignant gliomas J Neurosurg 94 2001 433 436
18. R.J. Young, A. Gupta, A.D. Shah, and et al. Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma Neurology 76 2011 1918 1924
19. P.Y. Wen, D.R. Macdonald, D.A. Reardon, and et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group J Clin Oncol Off J Am Soc Clin Oncol 28 2010 1963 1972
20. M. Castillo, J.K. Smith, L. Kwock, and et al. Apparent diffusion coefficients in the evaluation of high-grade cerebral gliomas AJNR Am J Neuroradiol 22 2001 60 64
21. A.I. Holodny, S. Makeyev, B.J. Beattie, and et al. Apparent diffusion coefficient of glial neoplasms: correlation with fluorodeoxyglucose-positron-emission tomography and gadolinium-enhanced MR imaging AJNR Am J Neuroradiol 31 2010 1042 1048
22. H.S. Kim, and S.Y. Kim A prospective study on the added value of pulsed arterial spin-labeling and apparent diffusion coefficients in the grading of gliomas AJNR Am J Neuroradiol 28 2007 1693 1699
23. P.A. Hein, C.J. Eskey, J.F. Dunn, and et al. Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury AJNR Am J Neuroradiol 25 2004 201 209
24. C. Asao, Y. Korogi, M. Kitajima, and et al. Diffusion-weighted imaging of radiation-induced brain injury for differentiation from tumor recurrence AJNR Am J Neuroradiol 26 2005 1455 1460
25. Y. Wang, M. Liu, J. Li, and et al. Application value of apparent diffusion coefficient in differentiation of brain radiation-injuries and glioma recurrence Zhongguo Yi Xue Ke Xue Yuan Xue Bao 34 2012 396 400
26. D. Pauleit, K.-J. Langen, F. Floeth, and et al. Can the apparent diffusion coefficient be used as a noninvasive parameter to distinguish tumor tissue from peritumoral tissue in cerebral gliomas? J Magn Reson Imaging 20 2004 758 764
27. Y. Bilgili, and B. Unal Effect of region of interest on interobserver variance in apparent diffusion coefficient measures AJNR Am J Neuroradiol 25 2004 108 111
28. P. McGraw, L. Liang, and J.M. Provenzale Evaluation of normal age-related changes in anisotropy during infancy and childhood as shown by diffusion tensor imaging AJR Am J Roentgenol 179 2002 1515 1522
29. V. Sehgal, Z. Delproposto, D. Haddar, and et al. Susceptibility-weighted imaging to visualize blood products and improve tumor contrast in the study of brain masses J Magn Reson Imaging 24 2006 41 51
30. H.S. Kim, G.-H. Jahng, C.W. Ryu, and et al. Added value and diagnostic performance of intratumoral susceptibility signals in the differential diagnosis of solitary enhancing brain lesions: preliminary study AJNR Am J Neuroradiol 30 2009 1574 1579
31. K. Pinker, I.M. Noebauer-Huhmann, I. Stavrou, and et al. High-resolution contrast-enhanced, susceptibility-weighted MR imaging at 3T in patients with brain tumors: correlation with positron-emission tomography and histopathologic findings AJNR Am J Neuroradiol 28 2007 1280 1286
32. O. Tynninen, H.J. Aronen, M. Ruhala, and et al. MRI enhancement and microvascular density in gliomas. Correlation with tumor cell proliferation Invest Radiol 34 1999 427 434
33. D. Fahrendorf, W. Schwindt, J. Wölfer, and et al. Benefits of contrast-enhanced SWI in patients with glioblastoma multiforme Eur Radiol 23 2013 2868 2879
34. M. Hori, H. Mori, S. Aoki, and et al. Three-dimensional susceptibility-weighted imaging at 3 T using various image analysis methods in the estimation of grading intracranial gliomas Magn Reson Imaging 28 2010 594 598
35. A.A. Sayyari, R. Buckley, C. McHenery, and et al. Distinguishing recurrent primary brain tumor from radiation injury: a preliminary study using a susceptibility-weighted MR imaging-guided apparent diffusion coefficient analysis strategy AJNR Am J Neuroradiol 31 2010 1049 1054
36. J.-L. Xu, Y.-L. Li, J.-M. Lian, and et al. Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging Neuroradiology 52 2010 1193 1199
37. G.A. Alexiou, A. Zikou, S. Tsiouris, and et al. Comparison of diffusion tensor, dynamic susceptibility contrast MRI and 99mTc-tetrofosmin brain SPECT for the detection of recurrent high-grade glioma Magn Reson Imaging 32 2014 854 859
38. P.C. Sundgren, X. Fan, P. Weybright, and et al. Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast-enhancing lesions Magn Reson Imaging 24 2006 1131 1142
39. S.J. Price, R. Jena, N.G. Burnet, and et al. Predicting patterns of glioma recurrence using diffusion tensor imaging Eur Radiol 17 2007 1675 1684
40. P. Svolos, E. Kousi, E. Kapsalaki, and et al. The role of diffusion and perfusion weighted imaging in the differential diagnosis of cerebral tumors: a review and future perspectives Cancer Imaging 14 2014 20
41. L.S. Hu, L.C. Baxter, K.A. Smith, and et al. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements AJNR Am J Neuroradiol 30 2009 552 558
42. M. Vrabec, S. Van Cauter, U. Himmelreich, and et al. MR perfusion and diffusion imaging in the follow-up of recurrent glioblastoma treated with dendritic cell immunotherapy: a pilot study Neuroradiology 53 2011 721 731
43. R.F. Barajas, J.S. Chang, M.R. Segal, and et al. Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging Radiology 253 2009 486 496
44. R.J. Young, A. Gupta, A.D. Shah, and et al. MRI perfusion in determining pseudoprogression in patients with glioblastoma Clin Imaging 37 2013 41 49
45. R. Mangla, G. Singh, D. Ziegelitz, and et al. Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma Radiology 256 2010 575 584
46. M.E. Hegi, A.-C. Diserens, T. Gorlia, and et al. MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 2005 997 1003
47. D.-S. Kong, S.T. Kim, E.-H. Kim, and et al. Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status AJNR Am J Neuroradiol 32 2011 382 387
48. C.H. Suh, H.S. Kim, Y.J. Choi, and et al. Prediction of pseudoprogression in patients with glioblastomas using the initial and final area under the curves ratio derived from dynamic contrast-enhanced T1-weighted perfusion MR imaging AJNR Am J Neuroradiol 34 2013 2278 2286
49. M. Ibaraki, H. Ito, E. Shimosegawa, and et al. Cerebral vascular mean transit time in healthy humans: a comparative study with PET and dynamic susceptibility contrast-enhanced MRI J Cereb Blood Flow Metab 27 2006 404 413
50. E.S. Paulson, and K.M. Schmainda Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors Radiology 249 2008 601 613
51. M. Haris, N. Husain, A. Singh, and et al. Dynamic contrast-enhanced derived cerebral blood volume correlates better with leak correction than with no correction for vascular endothelial growth factor, microvascular density, and grading of astrocytoma J Comput Assist Tomogr 32 Nov 2008 955 965
52. S. Gahramanov, A.M. Raslan, L.L. Muldoon, and et al. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study Int J Radiat Oncol Biol Phys 79 2011 514 523
53. S. Gahramanov, L.L. Muldoon, C.G. Varallyay, and et al. Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival Radiology 266 2013 842 852
54. C.G. Varallyay, E. Nesbit, R. Fu, and et al. High-resolution steady-state cerebral blood volume maps in patients with central nervous system neoplasms using ferumoxytol, a superparamagnetic iron oxide nanoparticle J Cereb Blood Flow Metab 33 2013 780 786
55. P. Weybright, P.C. Sundgren, P. Maly, and et al. Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy AJR Am J Roentgenol 185 2005 1471 1476
56. H.-P. Schlemmer, P. Bachert, K.K. Herfarth, and et al. Kaick G van. Proton MR spectroscopic evaluation of suspicious brain lesions after stereotactic radiotherapy AJNR Am J Neuroradiol 22 2001 1316 1324
57. K. Ando, R. Ishikura, Y. Nagami, and et al. [Usefulness of Cho/Cr ratio in proton MR spectroscopy for differentiating residual/recurrent glioma from non-neoplastic lesions] Nihon Igaku Ho¯shasen Gakkai Zasshi Nippon Acta Radiol 64 2004 121 126
58. 1H MR-spectroscopy at 3.0 T in the differential diagnosis of recurrent or residual gliomas: a comparative study J Neurooncol 70 2004 49 58
59. C.F. Chuang, A.A. Chan, D. Larson, and et al. Potential value of MR spectroscopic imaging for the radiosurgical management of patients with recurrent high-grade gliomas Technol Cancer Res Treat 6 2007 375 382
60. R. Srinivasan, J.J. Phillips, S.R. Vandenberg, and et al. Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM Neuro Oncol 12 2010 1152 1161
61. E.E. Smith, K.R.N. Nandigam, Y.-W. Chen, and et al. MRI markers of small vessel disease in lobar and deep hemispheric intracerebral hemorrhage Stroke J Cereb Circ 41 2010 1933 1938
62. A.E. Elias, R.C. Carlos, E.A. Smith, and et al. MR spectroscopy using normalized and non-normalized metabolite ratios for differentiating recurrent brain tumor from radiation injury Acad Radiol 18 2011 1101 1108
63. Q.-S. Zeng, C.-F. Li, K. Zhang, and et al. Multivoxel 3D proton MR spectroscopy in the distinction of recurrent glioma from radiation injury J Neurooncol 84 2007 63 69
64. J.P. Rock, D. Hearshen, L. Scarpace, and et al. Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis Neurosurg 51 2002 912 920
65. Q.-S. Zeng, C.-F. Li, K. Zhang, and et al. Multivoxel 3D proton MR spectroscopy in the distinction of recurrent glioma from radiation injury J Neurooncol 84 2007 63 69
66. L.L. Wald, S.J. Nelson, M.R. Day, and et al. Serial proton magnetic resonance spectroscopy imaging of glioblastoma multiforme after brachytherapy J Neurosurg 87 1997 525 534
67. F. Träber, W. Block, S. Flacke, and et al. [1H-MR Spectroscopy of brain tumors in the course of radiation therapy: use of fast spectroscopic imaging and single-voxel spectroscopy for diagnosing recurrence] RöFo Fortschritte Auf Dem Geb Röntgenstrahlen Nukl 174 2002 33 42
68. J.D. Rabinov, P.L. Lee, F.G. Barker, and et al. In vivo 3-T MR spectroscopy in the distinction of recurrent glioma versus radiation effects: initial experience Radiology 225 2002 871 879
69. 18F] fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain Radiology 144 1982 885 889
70. 82Rb positron emission tomography J Comput Assist Tomogr 11 1987 563 570
71. P.E. Valk, T.F. Budinger, V.A. Levin, and et al. PET of malignant cerebral tumors after interstitial brachytherapy J Neurosurg 69 1988 830 838
72. Y. Ozsunar, M.E. Mullins, K. Kwong, and et al. Glioma recurrence versus radiation necrosis? A pilot comparison of arterial spin-labeled, dynamic susceptibility contrast enhanced MRI, and FDG-PET imaging Acad Radiol 17 2010 282 290
73. E.E. Kim, S.K. Chung, T.P. Haynie, and et al. Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG PET Radiogr Rev Publ Radiol Soc N Am Inc 12 1992 269 279
74. P.E. Ricci, J.P. Karis, J.E. Heiserman, and et al. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? AJNR Am J Neuroradiol 19 1998 407 413
75. 18F-FDG PET imaging of temporal lobe epilepsy Clin Nucl Med 39 2014 819 821
76. 18F]fluorodeoxyglucose PET with glucose loading J Comput Assist Tomogr 18 1994 12 15
77. 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter J Nucl Med 45 2004 1653 1659
78. K. Miwa, M. Matsuo, S.-i. Ogawa, and et al. Re-irradiation of recurrent glioblastoma multiforme using 11 C-methionine PET/CT/MRI image fusion for hypofractionated stereotactic radiotherapy by intensity modulated radiation therapy Radiat Oncol 9 2014 181
79. 18F-FDG PET Eur J Nucl Med Mol Imaging 29 2002 176 182
80. 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value Eur J Nucl Med Mol Imaging 32 2005 39 51
81. N. Tsuyuguchi, T. Takami, I. Sunada, and et al. Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery in malignant glioma Ann Nucl Med 18 2004 291 296
82. 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy J Nucl Med 49 2008 694 699
83. M. Tripathi, R. Sharma, R. Varshney, and et al. Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors Clin Nucl Med 37 2012 158 163
84. 11C-methionine PET and perfusion MRI Clin Neurol Neurosurg 112 2010 758 765
85. 18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas Neurosurgery 57 2005 505 511
86. 18F]fluoroethyl)-l-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment J Neurooncol 88 2008 27 35
87. 18F-FDG PET and evaluation of diagnostic accuracy J Nucl Med 47 2006 904 911
88. C.J. Ledezma, W. Chen, V. Sai, and et al. 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience Eur J Radiol 71 2009 242 248
89. 18F-FDG-PET in the clinical assessment of glioma recurrence Eur J Nucl Med Mol Imaging 35 2008 966 975
90. 201Tl-SPECT J Clin Neurosci Off J Neurosurg Soc Australas 15 2008 1327 1334
91. J.L. Kline, R.B. Noto, and M. Glantz Single-photon emission CT in the evaluation of recurrent brain tumor in patients treated with gamma knife radiosurgery or conventional radiation therapy AJNR Am J Neuroradiol 17 1996 1681 1686
92. 201Tl SPET in the detection of recurrent brain tumours after radiation therapy Nucl Med Commun 23 2002 1183 1190
93. 99mTc-HMPAO AJNR Am J Neuroradiol 12 1991 1187 1192
94. Y. Yoshii, M. Satou, T. Yamamoto, and et al. The role of thallium-201 single photon emission tomography in the investigation and characterisation of brain tumours in man and their response to treatment Eur J Nucl Med 20 1993 39 45
95. F.P. Le Jeune, F. Dubois, S. Blond, and et al. Sestamibi technetium-99m brain single-photon emission computed tomography to identify recurrent glioma in adults: 201 studies J Neurooncol 77 2006 177 183
96. A. Soricelli, A. Cuocolo, A. Varrone, and et al. Technetium-99m-tetrofosmin uptake in brain tumors by SPECT: comparison with Thallium-201 imaging J Nucl Med 39 1998 802 806
97. S. Barai, Rajkamal null, G.P. Bandopadhayaya, and et al. Thallium-201 versus Tc99m-glucoheptonate SPECT for evaluation of recurrent brain tumours: a within-subject comparison with pathological correlation J Clin Neurosci Off J Neurosurg Soc Australas 12 2005 27 31
98. Q.-S. Zeng, C.-F. Li, H. Liu, and et al. Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging Int J Radiat Oncol Biol Phys 68 2007 151 158
99. R. Prat, I. Galeano, A. Lucas, and et al. Relative value of magnetic resonance spectroscopy, magnetic resonance perfusion, and 2-(18F) fluoro-2-deoxy-d-glucose positron emission tomography for detection of recurrence or grade increase in gliomas J Clin Neurosci Off J Neurosurg Soc Australas 17 2010 50 53
100. E. Matsusue, J.R. Fink, J.K. Rockhill, and et al. Distinction between glioma progression and post-radiation change by combined physiologic MR imaging Neuroradiology 52 2010 297 306
101. 18F]fluoroethyl-l-tyrosine and magnetic resonance spectroscopy J Neurosurg 102 2005 318 327
102. H.J. Baek, H.S. Kim, N. Kim, and et al. Percent change of perfusion skewness and kurtosis: a potential imaging biomarker for early treatment response in patients with newly diagnosed glioblastomas Radiology 264 2012 834 843
103. J. Cha, S.T. Kim, H.-J. Kim, and et al. Differentiation of tumor progression from pseudoprogression in patients with posttreatment glioblastoma using multiparametric histogram analysis AJNR Am J Neuroradiol 35 2014 1309 1317